

IN THE CLAIMS

Kindly amend claims 3, 4, 6, 9, 10, 13, 17 and 18 under the provisions of 37 CFR§1.121(a) by deleting the bracketed subject matter and inserting the underlined material:


Sub B4  
3. (amended) The polyurethane according to [any of] claim[s] 1 [and 2], wherein the starting sulphated hyaluronic acid is selected from the group consisting of:

- A<sub>1</sub>) O-sulphated hyaluronic acid, and  
B<sub>2</sub>) N-sulphated hyaluronic acid.


4. (amended) The polyurethane according to [any of] claim[s] 1 [and 2], wherein the starting sulphated hyaluronic acid derivative is selected from the group consisting of:

- A<sub>2</sub>) O-sulphated hyaluronic acid derivative, and  
B<sub>2</sub>) N-sulphated hyaluronic acid derivative.

Sub B6  
6. (amended) The polyurethane according to [any of] claim[s] 1[-5] of formula (1)



or formula (II)



wherein PU is a residue of the polyurethane chain, Hsulph is a residue of the sulphated hyaluronic acid or a sulphated hyaluronic acid derivative containing at least one free carboxylic function.

A<sup>3</sup>

9. (amended) Haemocompatible material comprising at least one polyurethane according to [any of] claim[s] 1[-6].

10. (amended) Haemocompatible material consisting of at least one polyurethane according to [any of] claim[s] 1[-6].